Background and objective AKT2 is a critical actor in the PI3K signal transduction pathway Activation of AKT2 can lead to cell growth and survival.It has been revealed that AKT2 play a central role in tumorigenesis, tumor growth as well as metastasis.The aim of this study is to investigate the association between AKT2 and the clinical outcome of non-small cell lung cancer (NSCLC) patients by detecting its expression levels in the tumor tissue samples.Methods We developed an immunohistochemistry (IHC) assay to measure AKT2 protein levels in lung specimens from 80 cases with NSCLC and 10 cases with benign pulmonary disease.Results The positive rate of AKT2 was 57.50％ (46/80) in NSCLC, which was higher than that in benign pulmonary (10.0％) samples (X2=8.038, P=0.006).Ihere was no significant correlation between AKT2 expression and the clinicopathologic profiles.The expression of AKT2 was significantly correlated with the progression free survival (PFS) ( X2=l2.671, P=0.005) and the overall survival (OS) (X2=9.851, P=0.021) of patients with NSCLC.Conclusion AKT2 may provide a prognostic bio-marker of NSCLC.%背景与目的 AKT2是P13K信号传导通路中重要因子,AKT2激活导致细胞生长和生存,近年来,许多研究表明AKT2在肿瘤形成、生长及转移中起着重要作用.本研究通过检测肿瘤组织中AKT2的表达水平,旨在研究AKT2在非小细胞肺癌(non-small cell lung cancer,NSCLC)中的表达及其与临床预后的关系.方法通过免疫组化方法检测80例NSCLC及10例肺良性病变的组织标本中AKT2蛋白水平.结果NSCLC中AKT2表达的阳性率为57.50%(46/80).明显高于肺良性病变组织(1/10,10.096)中的表达,具有统计学差异(X2=8.038,P=0.006).AKT2表达与NSCLC患者临床病理特征无明显关系.AKT2表达与患者无进展生存期(X2=12.671,P=0.005)及总生存期(X2=9.851,P=0.021)有明显关系.结论 NSCLC中AKT2是患者预后不良的生物学标志.
展开▼
